Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
BlossomHill eyes IPO to grow taller in crowded cancer fields
The biotech’s lead asset is a macrocyclic EGFR-targeting molecule going up against AstraZeneca’s approved lung cancer drug, Tagrisso.
Darren Incorvaia
Jul 17, 2026 12:08pm
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
May 7, 2026 11:15am
Recursion's new CEO is bringing the AI outfit back to earth
May 6, 2026 6:30am
AbbVie dips into boiling RAS waters with $1.45B biobucks deal
Apr 28, 2026 10:01am
Rebranded biotech lands $125M for rescued Galapagos assets
Apr 28, 2026 7:00am
Astellas thins early pipeline, swaps out struggling gene therapy
Apr 27, 2026 10:38am
